Most frequent side effects are nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre.<ref>{{Cite journal

 
| pages = 25–51

 
| year = 1986

 
| pmid = 3516579

 
| doi = 10.1185/03007998609111089

 
| issue = 1

 
| volume = 10 | first1 = C.

 
| title = The safety of bromocriptine in long-term use: a review of the literature

 
| journal = Current medical research and opinion

 
| last1 = Weil

 
}}</ref> Vasospasms with serious consequences such as myocardial infarction and stroke that have been reported in  connection with the [[puerperium]], appear to be extremely rare events.<ref>{{Cite journal

 
| last1 = Iffy

 
| first1 = L

 
| last2 = McArdle

 
| first2 = JJ

 
| last3 = Ganesh

 
| first3 = V

 
| last4 = Hopp

 
| first4 = L

 
| title = Bromocriptine related atypical vascular accidents postpartum identified through medicolegal reviews

 
| journal = Medicine and law

 
| volume = 15

 
| issue = 1

 
| pages = 127–34

 
| year = 1996

 
| pmid = 8691994

 
}}</ref>  Peripheral vasospasm (of the fingers or toes) can cause [[Raynaud's Phenomenon]]. 

 
Bromocriptine use has been anecdotally associated with causing or worsening [[psychosis|psychotic]] symptoms (its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine).<ref>{{Cite journal

 
| issue = 1

 
| pages = 87–95

 
| year = 1995

 
| pmid = 7701022

 
| volume = 66

 
| journal = The Psychiatric quarterly

 
| last1 = Boyd

 
| title = Bromocriptine and psychosis: a literature review

 
| doi = 10.1007/BF02238717 | first1 = A.

 
}}</ref>

 
[[Pulmonary fibrosis]] has been reported when bromocriptine was used in high doses for the treatment of Parkinson's disease.<ref>{{Cite journal

 
| journal = Clinical and experimental neurology

 
| volume = 27

 
| pages = 79–82

 
| year = 1990

 
| title = Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease

 
| last1 = Todman

 
| last2 = Oliver

 
| pmid = 2129961

 
| last3 = Edwards | first1 = D. | first2 = W. | first3 = R.

 
}}</ref>

 


 
Use to suppress milk production after childbirth was reviewed in 2014 and it was concluded that in this context a causal association with serious cardiovascular, neurological or psychiatric events could not be excluded with an overall incidence rate estimated to range between 0.005% and 0.04%. Additional safety precautions and stricter prescribing rules were suggested based on the data.<ref>[http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/08/news_detail_002157.jsp&mid=WC0b01ac058004d5c1 EMA Statement "CMDh endorses restricted use of bromocriptine for stopping breast milk production"]</ref><ref>http://m.aerzteblatt.de/news/59857.htm "EMA rät vom Abstillmittel Bromocriptin ab", article in [[Ärzteblatt]]</ref>  It is a bile salt export pump inhibitor.<ref>{{cite journal |last1=Montanari |first1=Floriane |last2=Pinto |first2=Marta |last3=Khunweeraphong |first3=Narakorn |last4=Wlcek |first4=Katrin |last5=Sohail |first5=M. Imran |last6=Noeske |first6=Tobias |last7=Boyer |first7=Scott |last8=Chiba |first8=Peter |last9=Stieger |first9=Bruno |last10=Kuchler |first10=Karl |last11=Ecker |first11=Gerhard F. |title=Flagging Drugs That Inhibit the Bile Salt Export Pump |journal=Molecular Pharmaceutics |volume=13 |issue=1 |pages=163–71 |year=2016 |pmid=26642869 |doi=10.1021/acs.molpharmaceut.5b00594 }}</ref>

 


 
After long-term use of [[dopamine agonist]]s, a [[withdrawal syndrome]] may occur during dose reduction or discontinuation with the following possible side effects:  anxiety, panic attacks, [[dysphoria]], depression, agitation, irritability, suicidal ideation, fatigue, [[orthostatic hypotension]], nausea, vomiting, [[diaphoresis]], generalized pain, and drug cravings. For some individuals, these withdrawal symptoms are short-lived and they make a full recovery, for others a [[protracted withdrawal syndrome]] may occur with withdrawal symptoms persisting for months or years.<ref name="pmid23686524">{{cite journal |vauthors=Nirenberg MJ |title=Dopamine agonist withdrawal syndrome: implications for patient care |journal=Drugs Aging |volume=30 |issue=8 |pages=587–92 |year=2013 |pmid=23686524 |doi=10.1007/s40266-013-0090-z }}</ref>

 

